The Journal of Pharmacology and Experimental Therapeutics · Nov 2026

Pseudocannabinoid, H4CBD, Enhances Lipid Catabolism to Reduce Visceral Adiposity and Large Adipocyte Size in Advanced Metabolic Syndrome

By Wilson JN, Mendez DA, Hernandez Garcia M et al.

Metabolic Syndrome (MetS) is a precursor for cardiovascular disease (CVD) and type 2 diabetes (T2D), with a current prevalence of 62.4% among US adults aged 60 years or older. Cannabidiol (CBD) use has risen, alongside interest in synthetic CBD analogues as safer, purer alternatives. However, the effects of chronic cannabinoid use during age-associated cardiometabolic dysfunction have not been examined. To assess the effects of 1,2,8,9-tetrahydrocannabidiol (H4CBD), a non-narcotic analogue of CBD, on advanced MetS, 41-week-old Otsuka Long-Evans Tokushima Fatty (OLETF) rats were administered 200 mg H4CBD/kg by oral gavage for 4 weeks. Animals were fed ad libitum and monitored alongside vehicle-treated OLETF and lean, strain-control Long-Evans Tokushima Otsuka (LETO) rats. Body mass (BM) was reduced by 0.72-fold in the H4CBD group compared to OLETF and was similar to LETO levels within the first week, but did not reverse the diabetic phenotype of the aged OLETF. H4CBD also reduced visceral fat mass (FM; 0.59-fold) and nearly ablated large adipocyte (>100 μm) abundance compared to OLETF. Plasma triglycerides were more than doubled in OLETF compared to LETO, and H4CBD normalized the levels. H4CBD increased urinary 3-methylhistidine to creatinine ratio by 1.77-fold, and while not statistically significant (p=0.07), this suggests that lean tissue was lost along with FM, contributing to the reduction in BM. These results suggest synthetic cannabinoids have potential for managing advanced-age obesity during MetS, even with consideration of possible cachexic effects. Significance statement: This study demonstrated that chronic administration of 1,2,8,9-tetrahydrocannabidiol (H4CBD) in aged rats with advanced Metabolic Syndrome (MetS) reduced adiposity, large adipocytes, and hepatic and plasma triglyceride content. This data highlights that cannabinoids may improve the MetS-associated adiposity and dyslipidemia by enhancing hepatic lipid metabolism. Moreover, despite the reduction in adiposity, urinary 3-methylhistadine (3MH), a marker of muscle wasting, was elevated, necessitating careful management among elderly cannabis users with MetS.

doi.org/10.1016/j.jpet.2026.105071Interventions

AgingResearch.News